Tatva Chintan Pharma Chem reported strong Q3 FY26 financial results.

Revenue from operations soared to 131.3 Cr, a 53% increase year-on-year.

Profit after tax (PAT) saw a significant jump to 15.2 Cr, marking a remarkable 10,889% YoY growth, with Earnings Per Share (EPS) at ₹6.49. For the nine months ending December 2025, revenue reached 371.7 Cr (up 35% YoY) and PAT was 31.7 Cr (up 578% YoY). Operational revenue in Q3 was primarily driven by Structure Directing Agents (41%) and Pharma & Agrochemical Intermediates (36%). A core strategy involves focusing on 'green' chemistry processes like electrolysis and continuous flow chemistry for sustainable solutions, reduced waste, and improved margins.

The company benefits from a diversified product portfolio in niche specialty chemicals, ongoing R&D, and high entry barriers in its segments.

The company is well-positioned to capitalize on India's expanding role in the global chemical market, driven by the 'China+1' policy and the industry's pivot towards sustainable products.

The global specialty chemicals market is projected to grow at a 7% CAGR, presenting significant future opportunities, supported by ongoing capital expenditure to boost capacities.